IL-2 T Cell Detection for Rapid Immunogenicity Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for evaluating the immunogenicity of pharmaceutical candidate substances are inefficient as they require a significant period to detect T cell proliferation, making them unsuitable for timely screening and selection of candidate substances.
Innovation Solution
A method involving the detection of IL-2-secreting T cells in a blood-derived cell population cultured with a test substance, specifically using antigen-presenting cells and CD4+ T cells, within 24 to 72 hours after initiation, to assess immunogenicity before active T cell proliferation occurs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If conventional methods are used to evaluate immunogenicity by detecting T cell proliferation, then the evaluation can be performed, but it takes a significant period of time (five to seven days or later)
Solution Approach 1:
The patent applies preliminary action by detecting IL-2 secretion at an early stage (24-72 hours) before T cell proliferation becomes active. This allows the evaluation to be performed in advance, significantly reducing the time required compared to conventional methods that wait for five to seven days or later for proliferation detection.
Solution Approach 2:
The patent substitutes the mechanical/proliferation-based detection system with a biochemical detection system. Instead of relying on T cell proliferation (a mechanical/cell division process), the method detects IL-2 secretion (a biochemical marker), which provides earlier and more rapid immunogenicity evaluation.
2Productivity
If T cell proliferation is used as an indicator for immunogenicity evaluation, then the evaluation can be performed, but the process is inefficient for screening and selection of candidate substances
Solution Approach 1:
The patent changes the evaluation parameter from T cell proliferation (which occurs after 5-7 days) to IL-2 secretion (which can be detected at 24-72 hours). This parameter change enables faster screening and selection of candidate substances, significantly improving productivity in the pharmaceutical development process.
3Loss of time
If conventional immunogenicity evaluation methods are used, then candidate substances can be screened, but the time and cost of the screening process is excessive
Solution Approach 1:
The patent performs the immunogenicity evaluation in advance at an early stage (24-72 hours) rather than waiting for T cell proliferation to occur after five to seven days. This preliminary action significantly reduces the time and cost of the screening process, making it more efficient for pharmaceutical development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for rapid evaluation and selection of pharmaceutical candidate substances with low or high immunogenicity, reducing the time and cost of the screening process while enabling more trial-and-error cycles.
Implementation Method 1
detecting IL-2-secreting T cells in the cell population cultured in step (a) at a time point during the early stage of IL-2 secretion
Data Source
AI summary
In one aspect, disclosed herein is a method for evaluating the immunogenicity of a test substance in a short period of time by using, as an indicator of the immunogenicity of the test substance, the proportion of IL-2-secreting cells in a T cell population (preferably a CD4+ T cell population) at a time point during the early stage of IL-2 secretion after stimulation of the T cell population with the test substance (preferably 24 hours to 72 hours after the stimulation with the test substance).